Research by two U.S.-based antibody discovery companies shows a rise and dominance of a mutant SARS-CoV-2 virus and identifies a new mechanism predicting a competitive advantage of the mutation. The mutation is predicted to induce a structural change in the spike protein of the virus that would enhance virus entry. The study, conducted by Antibody Solutions and Single Cell Technology (SCT), is available on Preprints.org…
Categories: Business news
Parent category for any related news regarding the business and operations at SCT.
Single Cell Technology adds to international porfolio of patents
Single Cell Technology has expanded its international patent portfolio, India Patent No. 296142 titled “Method of screening single cells for the production of biologically active agent” was issued on Apr. 25, 2018…
Two additional US Patents issued for Single Cell Technology
Single Cell Technology is proud to announce two new US patents issued, shoring up its intellectual property portfolio. US Patent No. 9,944,983, titled “Method of screening a plurality of single secreting cells for functional activity…
SCT Announces Partnership with Antibody Solutions at 2017 Antibody Engineering & Therapeutics Conference
Sunnyvale, Calif. (Dec. 4, 2017) – Antibody Solutions, a leader in discovery of therapeutic, biomarker and critical reagent antibodies, and Single Cell Technology, Inc. (SCT), a pioneer in single cell analysis technology, have launched a partnership…
Chair of the University of Pittsburgh Department of Immunology joins Single Cell Technology’s Scientific Advisory Board
San Jose, CA April 28, 2016 Single Cell Technology, Inc. (SCT) today announced the appointment of Mark J. Shlomchik, M.D., Ph.D. to its Scientific Advisory Board. Dr. Shlomchik currently surves as the Chair of the Department of Immunology, School of Medicine,…
SCT Completes their Antibody Discovery Portfolio with Third Patent
San Jose, CA May 9, 2016 Single Cell Technology, Inc. (SCT) today announced the completion of their antibody discovery intellectual property portfolio with the granting of their third United States patent, US Patent No. 9328172, “Method of obtaining antibodies…
Single Cell Technology and AB Biosciences announce collaboration
Single Cell Technology, Inc. (SCT) and AB Biosciences (ABB) today announced a collaboration to identify therapeutic antibodies. SCT will utilize its patented platform to massively screen plasma cells, measure the kinetics of secreted antibodies, and sequence the…
Single Cell Technology completes interim funding
Single Cell Technology, Inc., a biotechnology company focused on discovery and development of therapeutic antibodies using its proprietary Digital Antibodies engine to facilitate comprehensive multi-host campaigns, today announced that it completed its full…